Replies to post #83912 on Ocata Therapeutics Inc fka OCAT

[north40000]

There may be a reason for OCAT's recent decline in price/share: is the following that reason?

rumper and lasers, what kind of competition for OCAT will STEM provide, in light of its recent PR:

" ...Data from our dry age related macular degeneration study will be released in June at the 2015 ISSCR Annual Meeting."

"
StemCells, Inc. Reports First Quarter 2015 Financial Results and Provides Business Update
Tue May 5, 2015 4:05 PM|GlobeNewswire | About: STEM


NEWARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the first quarter 2015.

"StemCells, Inc. continues to make great progress," said Martin McGlynn, CEO of StemCells, Inc. "We have completed the enrollment of the first cohort in our Phase II Pathway StudyTM in cervical spinal cord injury. This cohort set medical history by successfully transplanting more neural stem cells into the human spinal cord than has ever been done previously. Based on the timing of completing cohort 1, we would expect to have interim six month results from this open label cohort available in the fourth quarter 2015. We will also be releasing top-line data from both of our Phase I/II studies shortly. Data from our thoracic spinal cord injury study will be released at the 4th ISCoS/ASIA Joint Scientific Meeting in May. Data from our dry age related macular degeneration study will be released in June at the 2015 ISSCR Annual Meeting."

First Quarter 2015 and Recent Highlights

In February 2015, Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine, and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration, presented findings on the safety and preliminary efficacy of our proprietary HuCNS-SC® human neural stem cells for dry age related macular degeneration (AMD) at the Angiogenesis, Exudation and Degeneration 2015 symposium.


"In May 2015, we held the investigator meeting for our Phase II RadiantTMstudy for dry Age Related Macular Degeneration. We are beginning the process of initiating our first clinical trial sites for this study."